Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms.

Mellinghoff, Ingo K; Chang, Susan M; Jaeckle, Kurt A; van den Bent, Martin

Mellinghoff, Ingo K; Chang, Susan M; Jaeckle, Kurt A; van den Bent, Martin.

Mellinghoff IK; Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Chang SM; Department of Neurological Surgery, University of California San Francisco, 505 Parnassus Room M 774SF, San Francisco, CA 94142-0112, USA.
Jaeckle KA; Department of Neurology and Oncology, Mayo Clinic Florida, Mangurian 4415, 4500 San Pablo Road, Jacksonville, FL 32224, USA.
van den Bent M; Department of Neuro-onoclogy, Brain Tumor Center at Erasmus MC Cancer Institute, Nt-542, Dr Molenwaterplein 40, Rotterdam 3015 GD, The Netherlands. Electronic address: m.vandenbent@erasmusmc.nl.

Hematol Oncol Clin North Am ; 36(1): 95-111, 2022 02.

Article en En | MEDLINE | ID: mdl-34711457

Asunto(s)

Neoplasias Encefálicas; Glioma; Leucemia Mieloide Aguda; Adulto; Neoplasias Encefálicas/genética; Neoplasias Encefálicas/terapia; Glioma/tratamiento farmacológico; Glioma/genética; Humanos; Isocitrato Deshidrogenasa/genética; Mutación

Palabras clave

Cancer metabolism; Isocitrate dehydrogenase (IDH); Low-grade glioma (LGG); Response assessment in neuro-oncology (RANO)

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Leucemia Mieloide Aguda / Glioma Límite: Adult / Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google